In the reward circuitry of the brain, a-7-nicotinic acetylcholine receptors (a7nAChRs) modulate effects of ∆ 9 -tetrahydrocannabinol (THC), marijuana's main psychoactive ingredient. Kynurenic acid (KYNA) is an endogenous negative allosteric modulator of a7nAChRs. Here we report that the kynurenine 3-monooxygenase (KMO) inhibitor Ro 61-8048 increases brain KYNA levels and attenuates cannabinoid-induced increases in extracellular dopamine in reward-related brain areas. In the selfadministration model of drug abuse, Ro 61-8048 reduced the rewarding effects of THC and the synthetic cannabinoid WIN 55,212-2 in squirrel monkeys and rats, respectively, and it also prevented relapse to drug-seeking induced by reexposure to cannabinoids or cannabinoid-associated cues. The effects of enhancing endogenous KYNA levels with Ro 61-8048 were prevented by positive allosteric modulators of a7nAChRs. Despite a clear need, there are no medications approved for treatment of marijuana dependence. Modulation of KYNA offers a pharmacological strategy for achieving abstinence from marijuana and preventing relapse.
a r t I C l e S The number of people seeking treatment for marijuana use in the United States per year (1, 243, 000) is higher than the number seeking treatment for cocaine or heroin use (787,000 or 507,000, respectively) 1 . Like other drugs of abuse, marijuana's rewarding effects involve neuro chemical changes in brain reward systems 2, 3 . Specifically, THC, the main psychoactive ingredient in marijuana, activates mesolim bic dopamine circuitry by enhancing the firing of dopamine neu rons in the ventral tegmental area (VTA) 4, 5 , resulting in increased release of dopamine from nerve terminals in the shell of the nucleus accumbens (NAc) 6, 7 .
Developing medications that modulate these effects of THC on reward signaling might provide a therapeutic approach for the treat ment of marijuana dependence. α7nAChRs are present in both the VTA and the NAc shell, where they are located on glutamatergic nerve terminals 8 . Their activation elicits the release of glutamate, which in turn acts at ionotropic glutamate receptors on dopaminergic terminals to stimulate dopamine release 9, 10 . We previously found that reward related behavioral and neurochemical effects of THC or the syn thetic cannabinoidreceptor agonist WIN 55,2122 could be blocked by methyllycaconitine (MLA), a selective antagonist at α7nAChRs, pointing to modulation of α7nAChR activity as a pharmacological approach for treating marijuana dependence 11, 12 . Unfortunately, systemic use of cholinergic antagonists acting directly at α7nAChRs is associated with central and peripheral side effects that limit their therapeutic utility 13, 14 . Medications that enhance the formation of endogenous negative allosteric modulators of α7nAChRs might be better tolerated than directly acting cholinergic antagonists [15] [16] [17] . Allosteric modulators change receptor conformations in the presence of orthosteric ligands and often have no effect on their own, acting only when physiological receptors are activated [15] [16] [17] .
Kynurenic acid (KYNA) is an endogenous neuroinhibitory metabo lite 18 . It is produced by the irreversible transamination of kynurenine, the first main catabolic product of tryptophan. Formed in astro cytes 19 , KYNA is present in the mammalian brain in nanomolar con centrations 20 . Long known as a competitive antagonist of the glycine coagonist site of the NMDA receptor 21 , KYNA is also a negative allosteric modulator of α7nAChRs at endogenous concentrations, and somatodendritic, preterminal and presynaptic α7nAChRs are equally sensitive to KYNA [22] [23] [24] . Notably, fluctuations in brain KYNA have neuromodulatory consequences. Thus, reductions in brain KYNA a r t I C l e S cause an increase in extracellular acetylcho line, dopamine and glutamate [25] [26] [27] , whereas KYNA elevations reduce α7nAChR func tion and result in α7nAChRdependent, but relatively modest, decreases in extracellular glutamate and dopamine in the striatum, pre frontal cortex and caudate nucleus 26, 28, 29 . It has therefore been proposed that astrocyte derived KYNA, through this indirect action, may serve as an endogenous modulator of both physiological and pathological gluta matergic and dopaminergic signaling 30 .
We hypothesized that pharmacological enhancement of brain KYNA levels could selectively counteract the behavioral and neurochemical effects of THC responsible for marijuana abuse and dependencenotably, the abilities to support the develop ment of persistent drugtaking behavior 31 , to precipitate relapse to drugseeking behavior in abstinent subjects 32 and to increase dopamine release in the nucleus accumbens shell 6, 7 . Production of KYNA in the brain and elsewhere can be increased by inhibiting kynurenine 3monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan degradation 33, 34 . In both rodents and monkeys, peripheral KMO inhibition results in elevated blood levels of KYNA's precursor kynurenine 35, 36 , which readily pen etrates the bloodbrain barrier and accumulates in astrocytes, where it undergoes transamination to KYNA 19, 37 . Newly formed KYNA is promptly released into the extracellular compartment 38 . Notably, no reuptake processes exist for KYNA, and extracellular KYNA is not degraded enzymatically 39 but is slowly eliminated from the brain by a nonspecific acid transporter 20, 40 .
In this study, we used 3,4dimethoxyN[4(3nitrophenyl)thiazol 2yl]benzenesulfonamide (Ro 618048), a potent, selective, peri pherally acting KMO inhibitor 41 , to indirectly increase brain KYNA. We combined neurochemical and behavioral approaches to evalu ate effects of Ro 618048 on (i) KYNA levels in the VTA and NAc shell in rats; (ii) elevations of extracellular dopamine in the NAc shell and VTA induced by THC or the synthetic cannabinoid WIN 55,2122 in rats; (iii) THC selfadministration in squirrel monkeys and WIN 55,2122 selfadministration in rats; (iv) druginduced and cueinduced relapse to cannabinoidseeking behavior in abstinent animals; (v) cocaine selfadministration and foodrewarded behav ior in monkeys, to assess specificity of the effect; and (vi) working memory and THC discrimination in rats and squirrel monkeys, to assess potential side effects. To further elucidate the mechanism of the observed effects, we determined whether infusing KYNA locally in the NAc shell would prevent THCinduced elevations of dopamine in the NAc shell of rats.
RESULTS

Neurochemical effects of KMO inhibition in rats
We tested whether systemic administration of the KMO inhibitor Ro 618048 would increase levels of KYNA in two brain regions impli cated in rewarding effects of cannabinoids: the NAc shell and VTA. In vivo microdialysis experiments in freely moving rats showed that systemic administration of 30 and 100 mg per kilogram body weight intraperitoneally (i.p.) of Ro 618048 increased extracellular KYNA in the NAc shell by ~150% and ~225%, respectively ( Fig. 1a ; 30 mg per kg: F 11,55 = 28.59, P < 0.001; 100 mg per kg: F 11,55 = 15.03, P < 0.001).
In the VTA, the 30 and 100 mg per kg doses of Ro 618048 elevated KYNA by ~50% and ~200%, respectively ( Fig. 1b ; 30 mg per kg: F 11,55 = 5.85, P < 0.001; 100 mg per kg: F 11,55 = 24.18, P < 0.001). Peak KYNA levels in both NAc and VTA were observed 80 min after injec tion of 100 mg per kg Ro 618048 and 140 min or later after injection of 30 mg per kg Ro 618048.
We then determined whether systemic administration of Ro 618048 would block THCinduced elevations of dopamine in the NAc shell and VTA in rats. In the NAc shell, THC (3 mg per kg, i.p.) significantly increased extracellular dopamine ( Fig. 2a,b ; treatment × time interaction, F 30,218 = 1.99, P < 0.003; area under the curve (AUC), F 3,22 = 6.06, P = 0.0036), but pretreatment with 30 or 100 mg per kg of Ro 618048 dosedependently blocked this effect of THC ( Fig. 2a,b) . We saw similar effects in the VTA, where THC (3 mg per kg) also increased extracellular dopamine significantly ( Fig. 2c,d ; treatment × time interaction, F 30,188 = 4.25, P < 0.0001; AUC, F 3,19 = 22.01, P < 0.001), and pretreatment with either 30 or 100 mg per kg of Ro 618048 significantly reduced this effect of THC ( Fig. 2c,d) . When given alone, Ro 618048 (100 mg per kg) did not significantly affect dopamine levels in either the NAc ( Fig. 2a ; P = 0.99) or the VTA ( Fig. 2c ; P = 0.93).
This finding that systemic administration of Ro 618048 blocked the effects of THC on dopamine in rewardrelated brain areas, coupled with the finding that Ro 618048 increased KYNA in these areas, led us to determine whether the effects of THC on dopamine could be blocked by infusing KYNA directly into the NAc shell. We observed that THC (3 mg per kg, i.p.) significantly increased extra cellular dopamine in the NAc shell of freely moving rats when the local tissue was continuously infused with vehicle, but not when the tissue was continuously infused with KYNA (500 nM) ( Fig. 2e ,f: treatment × time interaction, F 14, 91 = 3.61, P < 0.0001; AUC: F 2,13 = 13.64, P = 0.0006). In the absence of THC, local infusion of KYNA (500 nM) into the NAc shell had no effect on dopamine levels ( Fig. 2e,f) .
To verify that the ability of Ro 618048 to block THCinduced dopamine elevations in the NAc shell was due its actions at α7nAChRs, we reversed the effects of Ro 618048 with galantamine and PNU120596, both agonists at the allosteric potentiating site of α7nAChRs where KYNA acts 23, 42 . In these two experiments (one with galantamine and one with PNU120596), we again found that systemic Ro 618048 (100 mg per kg, i.p.) significantly decreased the ability of THC (3 mg per kg, i.p.) to raise dopamine in the NAc Fig. 2a,b) , reducing the AUC by about 60 to 70% ( Fig. 3a ; F 5,27 = 8.34, P < 0.001; Fig. 3b ; F 4,17 = 9.87, P < 0.0003). Furthermore, we observed that pretreatment with galantamine ( Fig. 3a; 3 mg per kg, i.p.) or PNU120596 ( Fig. 3b ; 1 mg per kg, i.p.) reversed this effect of Ro 618048. Neither galan tamine nor PNU120596 altered dopamine levels when given alone, nor did they alter the effects of THC ( Fig. 3a,b) . Thus, we confirmed that α7nAChRs were involved in the ability of Ro 618048 to block THCinduced dopamine elevations in rats.
To determine whether treatment with Ro 618048 alters the effects of cannabinoid CB 1 receptor agonists other than THC, we studied dopamine elevations induced by the synthetic agonist WIN 55,2122. Like THC, WIN 55,2122 (0.3 mg per kg intravenously (i.v.)) signi ficantly increased extracellular dopamine in the NAc shell ( Fig. 4a ; treatment × time interaction, F 28,98 = 3.28, P < 0.0001). Although Ro 618048 (30 or 100 mg per kg) alone did not affect dopamine levels ( Fig. 4b; both P values = 0.99), pretreatment with 30 or 100 mg per kg of Ro 618048 significantly reduced the ability of WIN 55,2122 to increase dopamine in the NAc shell ( Fig. 4a,c ; AUC: F 4,14 = 3.73, P = 0.0288).
Behavioral effects of KMO inhibition in rats
Having determined that the KMO inhibitor Ro 618048 could block the effects of cannabinoid CB 1 agonists in rewardrelated brain areas, we tested the effects of this treatment in behavioral models of cannabi noid abuse. We first turned to a rodent model of cannabinoid rein forcement in which rats intravenously selfadminister WIN 55,2122 (12.5 µg per kg per injection). This synthetic cannabinoid had a clear reinforcing effect, causing rats to respond significantly more on the lever that delivered the drug than on an inactive control lever ( Fig. 4d,e ; F 1,4 = 23.95, P = 0.008). Treatment with 30 or 100 mg per kg Ro 618048 40 min before each session significantly decreased self administration of WIN 55,2122 ( Fig. 4d , 30 mg per kg: F 3,12 = 19.5, P < 0.001; Fig. 4e , 100 mg per kg: F 3,12 = 6.92, P = 0.006). The 100 mg per kg dose of Ro 618048 decreased selfadministration responses (on the active lever) over all 3 d of testing, but it also signifi cantly affected responses on the inactive lever ( Fig. 4e ; F 3,12 = 18.35, P < 0.001). This effect on inactivelever responses was not seen with 30 mg per kg Ro 618048 ( Fig. 4d ; F 3,12 = 1.76, P = 0.21), yet this lower dose was effective in blocking the selfadministration of WIN 55,2122. npg a r t I C l e S Selfadministration quickly recovered to baseline levels when Ro 618048 treatment was discontinued. As relapse to drug use after long periods of abstinence represents one of the greatest challenges for the treatment of addiction, we also investigated whether Ro 618048 would block reinstatement of drug seeking by abstinent rats in an animal model of relapse. When WIN 55,2122 delivery was discontinued, rats' drugseeking behavior decreased to low levels ( Fig. 4f) . A noncontingent priming injection of WIN 55,2122 (0.3 mg per kg., i.p., 10 min before the session) reinstated drugseeking behavior, but this relapselike effect was completely blocked by pretreatment with 100 mg per kg Ro 618048 ( Fig. 4f ; F 5,20 = 231.13, P < 0.001). None of these treatments signi ficantly affected responses on the inactive lever ( Fig. 4f ; both treat ment P values = 0.51). Thus, Ro 618048 prevented the relapselike effect induced by reexposure to cannabinoids in rats.
KMO inhibition and THC reward in squirrel monkeys
Because THC selfadministration in squirrel monkeys provides the most congruent animal model of human cannabinoid abuse 31 , we used this model to examine the effects of Ro 618048. We also tested the effects of Ro 618048 in monkeys trained to selfadminister food and cocaine under the same schedule of reinforcement (fixedratio 10) to determine whether the effects of Ro 618048 are specific to cannabinoid reward.
At the peak of the THC selfadministration doseeffect curve (4 µg per kg per injection THC; Fig. 5a ), squirrel monkeys self administered an average of 50.80 ± 1.90 injections per session and leverpressed at an average rate of 1.20 ± 0.25 responses per sec ond in the presence of a green light signaling THC availability. We investigated selfadministration of this THC dose in monkeys across 3 consecutive days of treatment with Ro 618048 (10 or 20 mg per kg, 40 min before each session). Ro 618048 was always admin istered intramuscularly (i.m.) in monkeys. Ro 618048 significantly and dosedependently reduced THC selfadministration during all three sessions ( Fig. 5a ; 10 mg per kg Ro 618048: F 3,12 = 4.07, P = 0.033; 20 mg per kg Ro 618048: F 3,12 = 30.93, P < 0.001). Self administration behavior returned to baseline levels when Ro 618048 treatment ended.
In the food selfadministration model ( Fig. 5b) , monkeys self administered 53.46 ± 1.29 food pellets per session on average, with a response rate of 1.97 ± 0.66 responses per second in the presence of a green light signaling food availability. During three daily sessions with Ro 618048 pretreatment, foodreinforced response in mon keys was not affected by either 10 or 20 mg per kg of Ro 618048, under testing conditions that paralleled those used to evaluate THC selfadministration ( Fig. 5b ; 10 mg per kg Ro 618048: F 3,9 = 1.76, P = 0.22; 20 mg per kg Ro 618048: F 3,9 = 1.77, P = 0.22). Thus, Ro 618048 did not produce a nonspecific disruption of behavior.
Moreover, Ro 618048 (20 mg per kg, 40 min before the session) reversed the disruptive effects of THC (0.56 mg per kg i.v., imme diately before the session) on foodmaintained selfadministration behavior ( Supplementary Fig. 1a : pellets per session F 3,6 = 23.29, P = 0.001; post hoc analysis, THC 0.56 mg per kg versus Ro 618048 20 mg per kg + THC 0.56 mg per kg, P = 0.003; Supplementary  Fig. 1b : response rate F 3,6 = 15.37, P = 0.003; post hoc analysis, THC 0.56 mg per kg versus Ro 618048 20 mg per kg + THC 0.56 mg per kg, P = 0.018). Treatment with 0.56 mg per kg THC alone significantly reduced both the foodmaintained response rate (from 0.90 ± 0.17 to 0.09 ± 0.03 responses per second) and the number of food pellets per session (from 49.5 ± 1.76 to 19.00 ± 4.51) as compared to values observed after vehicle treatment (post hoc analysis, vehicle versus THC 0.56 mg per kg: response rate, P = 0.003; pellets per session, P = 0.002). Pretreatment with Ro 618048 had no effect by itself (post hoc analysis, vehicle versus Ro 618048 20 mg per kg: rate. P = 0.28; pellets. P = 0.93), but it completely reversed the effects of THC on response rate (to 0.62 ± 0.08 responses per second; post hoc analysis, vehicle versus Ro 618048 20 mg per kg + THC 0.56 mg per kg, P = 0.22) and food intake (to 46.67 ± 1.45 pellets per session; post hoc analysis, P = 0.91).
In monkeys trained to selfadminister cocaine (Fig. 5c) , the dose of Ro 618048 (20 mg per kg) that effectively decreased THC self administration did not alter cocaine selfadministration (30 µg per kg per injection). Monkeys averaged 44.56 ± 0.62 injections per session with a mean response rate of 0.54 ± 0.04 responses per second in the presence of a green light signaling cocaine availability. Pretreatment with Ro 618048 40 min before each of three daily sessions did not In monkeys selfadministering food or cocaine, response rates were not affected by treatment with Ro 618048 (Fig. 5e , food self administration: 10 mg per kg Ro 618048, F 3,9 = 1.1, P = 0.40; 20 mg per kg Ro 618048, F 3,9 = 1.61, P = 0.26; Fig. 5f , cocaine self administration: F 3,6 = 0.69, P = 0.59).
To further characterize the nature of the effects of Ro 618048 on THC selfadministration, we varied the dose of THC and obtained classic inverted Ushaped doseeffect curves (Fig. 5g,h) . THC main tained significantly more selfinjections (Fig. 5g ; F 6,22 = 29.34, P < 0.001) than vehicle at 0.5, 1, 2, 4 and 8 µg per kg per injection and significantly higher response rates ( Fig. 5h ; F 6,22 = 36.76, P < 0.001) than vehicle at 4 µg per kg per injection. We found that pretreat ment with 20 mg per kg of Ro 618048 significantly shifted the THC doseresponse curve for injections per session down and to the right ( Fig. 5g; interaction of THC and Ro 618048, F 5,17 = 35.45, P < 0.001), consistent with a decrease in THC's rewarding effects. This Ro 618048 dose also produced a significant downward and rightward shift for response rates (Fig. 5h; interaction of THC and Ro 618048, F 5,17 = 16.10, P < 0.001). Post hoc pairwise comparisons revealed sig nificant differences in the effects of 1, 2, 4 and 16 µg THC per kg per injection after Ro 618048 pretreatment on the number of self administered injections per session (all P < 0.001) and significant differences in effects of 2, 4 and 16 µg per kg THC per injection after Ro 618048 pretreatment on response rates (2 µg per kg, P = 0.04; 4 µg per kg, P < 0.001; 16 µg per kg, P = 0.012). The total amount of THC received during the session was significantly decreased by Ro 618048 across most of the doseeffect function ( Fig. 5i ; F 5,17 = 59.4, P < 0.001), but it increased at the highest dose per injection.
We then asked whether positive allosteric modulators of α7nAChRs (galantamine and PNU120596) would prevent the effects of Ro 618048 on THC selfadministration in monkeys. Galantamine Fig. 6c ; F 4,12 = 35.71, P < 0.0001) but had no significant effect when given alone ( Fig. 6d : F 3,9 = 1.98, P = 0.19). Thus, we confirmed that α7nAChRs were involved in the ability of Ro 618048 to block the reinforcing effects of THC in nonhuman primates.
KMO inhibition and relapse in squirrel monkeys
To further study the effects of KMO inhibition in animal models of relapse to THC seeking, we determined whether Ro 618048 blocked reinstatement induced by reexposure to THC or THCassociated cues in squirrel monkeys and whether α7nAChRs were involved in this blockade. When leverpress responses for THC had been extinguished by discontinuing THC delivery, administration of a noncontingent priming injection of THC (40 µg per kg, i.v.) before the session reinstated drugseeking (Fig. 6e , F 5,14 = 34.37, P < 0.001; Fig. 6f , F 5,13 = 77.81, P < 0.001). Treatment with Ro 618048 (20 mg per kg) blocked this THCinduced reinstatement ( Fig. 6e,f; both P < 0.001 versus THC), and pretreatment with either galantamine (3 mg per kg) or PNU120596 (1 mg per kg) prevented this blockade (Fig. 6e,f) . Ro 618048 alone did not reinstate drugseeking behavior (Fig. 6e,f) . Both galantamine and PNU120596 produced a low level of reinstatement of drugseeking behavior ( Fig. 6e , P = 0.033 versus vehicles; Fig. 6g , P = 0.012 versus vehicles), but this effect was significantly smaller than the reinstatement produced by a priming injection of THC ( Fig. 6e , P < 0.001 versus THC; Fig. 6f , P < 0.001 versus THC). Because relapse can be triggered by reexposure to drugrelated environmental cues, we looked at cueinduced reinstatement of THC seeking. When both THC delivery and presentation of cues signaling delivery of THC were discontinued, THC seeking by the monkeys decreased to very low levels (Fig. 6g,h) . When visual cue presenta tion was restored and i.v. vehicle was delivered contingent on lever response, THCseeking behavior was reinstated (Fig. 6g , F 5,13 = 21.16, P < 0.001; Fig. 6h , F 5,10 = 57.87, P < 0.001). This cueinduced rein statement was significantly decreased by Ro 618048 (20 mg per kg) ( Fig. 6g,h) . Pretreatment with either galantamine (3 mg per kg) or PNU120596 (1 mg per kg) prevented these effects of Ro 618048 (Fig. 6g,h) . When Ro 618048, galantamine or PNU120596 were given with the THC vehicle without presentation of cues, THC seeking behavior was not reinstated (Fig. 6g , post hoc analysis versus vehicle + no cues: Ro 618048, P = 0.95; galantamine, P = 1.00; Fig. 6h : Ro 618048, P = 0.79; PNU120596, P = 0.69). These results suggest that treatment with a KMO inhibitor could prevent relapse caused by reexposure to THC or to THCassociated cues, and that this effect of KMO inhibition occurs through an α7nAChR mediated mechanism.
Effects of KMO inhibition and THC on working memory
Because excessive levels of KYNA may be associated with cognitive impairment 43, 44 and because THC is well known to impair mem ory, we tested the effects of Ro 618048 on working memory in rats trained with a delayed nonmatchingtoposition procedure and in squirrel monkeys trained with a delayed matchingtosample pro cedure. In rats, THC (3 or 5.6 mg per kg) and Ro 618048 (100 mg per kg) were administered alone and in combination. Ro 618048 had no effect on memory when given alone (Fig. 7a) , but THC decreased accuracy in a delaydependent manner, consistent with a selective impairment of working memory (Fig. 7b) . Ro 618048 did (Fig. 7c,d) . The main effects of THC (F 2,13 = 13.56, P < 0.0001) and delay (F 4,28 = 47.34, P < 0.0001) were both significant, but the effects of Ro 618048 were not (P = 0.85). Paired comparisons indicated that both doses of THC significantly impaired working memory (P < 0.0035).
In squirrel monkeys, working memory was also impaired by THC alone (0.1 mg per kg) but not by Ro 618048 (20 mg per kg) alone (Fig. 7e,f) . THC at short delay values also decreased accuracy slightly in monkeys, suggesting that impairments might have been due in part to nonselective disruption by THC, similar to the disruptions in foodmaintained behavior described above. THCinduced impair ments in monkeys were reversed by Ro 618048 (Fig. 7f; main 
KMO inhibition and discriminative-stimulus effects of THC
To determine whether Ro 618048 could affect not only the reinforc ing effects of THC but also its subjective effects, we studied effects of Ro 618048 in rodent and primate models of cannabinoid discrimi nation. In rats trained to detect whether they had been injected with THC or its vehicle, lever selection was dose dependent, with maximal selection of the drug lever (99.66%) at the 3 mg per kg training dose of THC ( Fig. 8a ; F 5,40 = 28.03, P < 0.001). Notably, the THC doseeffect curve was not significantly shifted by treatment with either 30 or 100 mg per kg of Ro 618048 ( Fig. 8a; F 2 Figure 7 Effects of Ro 61-8048 and THC on working memory in rats and squirrel monkeys. (a-d) The 100 mg per kg dose of Ro 61-8048, which was effective in blocking the effects of THC in reward-related brain areas in rats, did not have deleterious effects on short-term memory in rats when given alone (a) or in combination with THC (3 or 5.6 mg per kg, i.p.; c,d) in a delayed nonmatching-to-position model of working memory. Both doses of THC significantly decreased accuracy (b; P < 0.007), but this was not exacerbated by Ro 61-8048 (c,d). (e,f) The 20 mg per kg dose of Ro 61-8048, which was effective in blocking the effects of THC in reward-related brain areas in monkeys, did not have deleterious effects on short-term memory in monkeys when given alone (e) or in combination with THC (f) in a delayed matching-to-sample model of working memory. THC (0.1 mg per kg, i.m.) significantly decreased accuracy (f), and this was reversed by Ro 61-8048 (f). Accuracy (percentage of trials with a correct response) is shown (means ± s.e.m.; n = 8 rats, n = 3 monkeys) as a function of delay and of drug treatment. Dosages are given in mg per kg. npg a r t I C l e S not disrupt foodreinforced behavior when given alone ( Fig. 8b ; F 2,16 = 0.53, P = 0.59) or in combination with different doses of THC ( Fig. 8b ; F 2,45 = 0.24, P = 0.79), indicating that decreases in WIN 55,2122 selfadministration produced by Ro 618048 in rats ( Fig. 4d,e) were not due to nonspecific behavioral disruption. In squirrel monkeys trained to discriminate the cannabinoid CB 1 agonist AM4054 (10 µg per kg) from vehicle, THC generalized to the cannabinoid CB 1 training stimulus in a dosedependent manner ( Fig. 8c ; F 3,6 = 864.0, P < 0.001). This doseeffect curve was signi ficantly shifted to the right by treatment with 20 mg per kg of Ro 618048 ( Fig. 8c ; F 2,15 = 152.32, P < 0.001) but not by 10 mg per kg of Ro 618048 ( Fig. 8c ; P = 0.58). Ro 618048 did not affect response rates in this task ( Fig. 8d ; F 2,11 = 4.54, P = 0.09).
DISCUSSION
The present results indicate that pharmacological modulation of brain KYNA levels by KMO inhibitors could provide an effective approach for the treatment of marijuana dependence. It is well established that THC, like other drugs of abuse, elevates extracellular dopamine in the NAc shell 2, 7, 11 , an effect that is mediated by cannabinoid CB 1 receptors and presumably underlies the rewarding and dependence inducing effects of marijuana. Systemic administration of the KMO inhibitor Ro 618048 in rats increased extracellular KYNA levels in the VTA and NAc shell and substantially reduced the ability of THC or the synthetic cannabinoid WIN 55,2122 to stimulate dopamine release in these areas. This blockade of THC's effects appears to be due to actions of KYNA in the NAc shell, as, like systemic administra tion, local infusion of KYNA into the shell also prevented THC from elevating extracellular dopamine levels.
Ro 618048 also counteracted the effects of THC and WIN 55,2122 in behavioral models of drug abuse. In rats, it markedly reduced selfadministration of the synthetic cannabinoid WIN 55,2122. In monkeys, Ro 618048 decreased the rewarding effects of THC, as demonstrated by a shift of the selfadministration doseresponse curves of THC down and to the right. After pretreatment with Ro 618048, THC intake was reduced over a wide range of THC doses and increased only at the highest THC dose. This increase is consist ent with a reduced rewarding effect of THC and may also be due to the reversal by Ro 618048 of ratedepressing effects of THC such as those we observed in monkeys selfadministering food.
Relapse to drug use (as opposed to initial achievement of absti nence) is typically the main obstacle to successful cessation of drug use. In abstinent monkeys with extensive histories of THC self administration, Ro 618048 prevented relapselike THCseeking behavior induced by reexposure to THC. Parallel effects occurred in rats, where Ro 618048 prevented druginduced seeking of WIN 55,2122. Moreover, Ro 618048 was able to block the relapse inducing effects of THCassociated cues in monkeys, suggesting that it might reduce drug craving in humans.
The ability of the KMO inhibitor Ro 618048 to reduce neuro chemical and behavioral effects of THC in rats and monkeys was prevented by galantamine, an agonist at the allosteric potentiating site of α7nAChRs that overlaps with the site where KYNA acts as an antagonist 24 . As galantamine is also a weak cholinesterase inhibi tor, we confirmed prevention of the effects of Ro 618048 using PNU120596, a selective positive allosteric modulator of α7nAChRs that does not inhibit cholinesterase 42 . These results indicate that the antiabuse actions of KMO inhibition are due to KYNAinduced nega tive allosteric modulation of α7nAChRs.
Although further experimentation will be required to fully eluci date the circuitry and mechanisms involved in KYNA's ability to block cannabinoid reward, the available evidence supports the following hypothesis. THC and WIN 55,2122 facilitate dopamine release in the NAc shell 5, 6, 45 , and this is believed to be due at least in part to activation of excitatory glutamatergic pyramidal neurons that project from the prefrontal cortex to the VTA and NAc shell 46, 47 . Because α7nAChRs are localized on the terminals of these glutamatergic cells 8 , negative allosteric modulation of α7nAChRs by KYNA could reduce the release of glutamate by these cells and thereby reduce glutamateinduced dopamine release in the VTA and NAc shell 9, 10, 45 . As elevated levels of dopamine in the NAc shell are considered central to the rewarding effects of cannabinoid drugs 2 and as local infusion of KYNA directly into the NAc shell was sufficient to completely block THCinduced dopamine elevations, it is likely that effects of KYNA in the shell of the NAc are a main factor underlying the ability of Ro 618048 to reduce the rewarding effects of cannabinoids.
The safety of KMO inhibitors in humans will have to be considered in translational studies. Although high levels of KYNA have been associated with cognitive deficits 43, 44 , Ro 618048 has anticonvulsant effects and neuroprotective effects in animal models of focal or global ischemia and lDOPA-induced dyskinesia 30 . In our experi ments, the effects of Ro 618048 were specific to cannabinoid reward and were not associated with adverse effects such as reduced appe tite or nonspecific suppression of behavior. Of special relevance, the modest increase in brain KYNA produced by Ro 618048 did not adversely affect working memory in rats or squirrel mon keys in tests highly sensitive to impairments induced by THC and other amnesic agents 48 . Moreover, in rats, KMO inhibition by itself neither produced THClike subjective effects nor altered the effects of THC itself, which most likely comprise both rewardrelated and nonreward components. However, in squirrel monkeys, KMO inhi bition attenuated the discriminativestimulus effects of THC. The reason(s) for this speciesspecific effect may be related to differences in cannabinoid mechanisms between rodents and primates 31 . Notably, moderate KMO inhibition did not affect baseline levels of dopamine in the NAc shell or VTA in the present study, and is known not to affect brain levels of the neurotoxic kynurenine pathway metabolites 3hydroxykynurenine and quinolinic acid 36 .
The decreases in cannabinoid selfadministration observed here were not due to nonspecific suppression of operant behavior. Although responses on an inactive lever were decreased along with those on the active lever in the WIN 55,2122 selfadministration experiment when rats received 100 mg per kg Ro 618048, the 30 mg per kg dose decreased WIN 55,2122 selfadministration without significantly affecting inactivelever responses. Moreover, the higher dose of Ro 618048 did not alter foodmaintained behavior in rats. In monkeys, Ro 618048 did not affect food or cocaine selfadministration behavior, and, in fact, it reversed rate depressant effects of THC on food selfadministration.
Taken together, our results suggest that KMO inhibitors could be safe and effective, decreasing cannabinoid reward and relapse at doses devoid of adverse behavioral or neurotoxic effects. Because enhancing endogenous KYNA levels counteracts the abuserelated effects of THC through negative allosteric modulation of α7nAChRs, rather than by direct interference with CB 1 receptor function, drugs such as Ro 618048 might be better tolerated than orthosteric inverse agonists or antagonists of CB 1 receptors, which can have adverse side effects due to actions at CB 1 receptors not directly related to THC abuse 49 .
A medication that would safely and effectively assist in the treat ment of marijuana dependence would be an important step forward in dealing with cannabisuse disorders. In the present study, KMO npg a r t I C l e S inhibition selectively blocked cannabinoid reward and also counter acted the ability of drugs and drugrelated cues to trigger relapse to cannabinoid seeking. As in rodent or nonhuman primate models of neurological diseases, where KMO inhibition provides marked benefits ranging from behavioral remediation to neuroprotec tion 35, 36, 50 , pharmacological elevation of brain KYNA offers an attrac tive strategy for treating human marijuana dependence.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
delayed nonmatching-to-position procedure in rats. The procedure was described previously 55 . Briefly, male LongEvans rats were trained in a chamber with a horizontal array of three apertures. During each trial, the house light was extinguished and one of the two side apertures (left or right) was lit from within as a sample. After two responses in the sample aperture, the aperture light was extin guished and the delay period began (0, 7, 14, 21 or 28 s, in pseudorandom order over trials). The first response in the center aperture after the designated delay lit both side apertures. If the rat responded correctly (that is, in the nonmatching aperture, opposite to the sample), it received a 45mg food pellet. The next trial began after a 15s timeout period with the house light on. Sessions lasted until 100 pellets were delivered or after 90 min. THC (3 or 5.6 mg per kg) was given i.p. 40 min b.s., and Ro 618048 (100 mg per kg) was given i.p. 100 min b.s. delayed matching-to-sample procedure in squirrel monkeys. The procedure was described in detail previously 56 . Briefly, male squirrel monkeys were trained in a customized touchscreen chamber 57 . Trials began with presentation of a 7 × 7 cm digital photograph (sample stimulus). After twenty touch responses to the sample, the stimulus was terminated and the delay period began (0, 2, 4, 8 or 16 s, in pseudorandom order over trials). Following the delay, two comparison stimuli were presented left and right of the midline. A touch response to the stimulus that matched the previously presented sample resulted in delivery of 0.15 ml of the sweetened condensed milk reinforcer followed by a 10s timeout period, whereas a mismatch immediately initiated the timeout. Daily sessions were composed of 60 trials (12 trials of each delay). THC (0.1 mg per kg) was given i.m. 30 min b.s., and Ro 618048 (20 mg per kg) was given i.m. 70 min b.s. tHc discrimination in rats. Rats were trained under a discretetrials schedule of food reinforcement (FR10, 45s timeout) in which responses on one lever produced food when an injection of THC (3 mg per kg, i.p., 30 min b.s.) was given and responses on the other lever produced food when a vehicle injection was given 58 . Sessions lasted for 20 pellets or 30 min. Ro 618048 (vehicle, 30 or 100 mg per kg, i.p., 70 min b.s.) and THC (vehicle, 0.3, 0.56, 1, 1.8 or 3 mg per kg, i.p., 30 min b.s.) were given before test sessions, up to twice a week. During test sessions, food was delivered whenever there were ten consecutive responses on either lever. tHc discrimination in squirrel monkeys. Squirrel monkeys responded under an FR10 schedule of stimulusshock termination to discriminate injection of the cannabinoid CB 1 agonist AM4054 (10 µg per kg, i.m., 50 min b.s.) from vehicle in a twolever drug discrimination procedure 59 . The two levers were designated as drug (AM4054) and saline levers, with assignment remaining the same for a subject throughout the study. A brief, lowintensity shock was scheduled for delivery every 10 s until either the FR10 was completed on the correct lever or 30 s elapsed, whichever came first. Training sessions ended upon completion of 20 trials. The test session consisted of four components of 10 trials, each compo nent beginning with a 10min timeout period. No shock deliveries were sched uled during test sessions. Cumulative dosing procedures were used to establish doseresponse relationships for the discriminativestimulus effects of THC (0.01-0.3 mg per kg, i.m., 30 min b.s.) administered i.m. at the onset of sequential 10min timeout periods. Modification of the discriminative stimulus effects of THC by Ro 618048 (vehicle, 10 or 20 mg per kg, i.m., 70 min b.s.) was studied by determining how pretreatment with Ro 618048 altered the position of the THC doseeffect function.
Statistical analysis. All data are presented as means ± s.e.m. The sample sizes were chosen on the basis of our previous experience with the procedures used, and they are adequate to detect meaningful differences between conditions. All data met the assumptions of the test with regard to the normality, skew and homogeneity of variance. All tests were twotailed. Rats were randomly assigned to the groups for betweengroups experiments in microdialysis experiments. Counterbalanced assignment of treatment order for withinsubject design was used in behavioral experiments. Experimenters were not blind to the treatment assignment.
Microdialysis data were expressed as a percentage of basal KYNA and dopamine values; basal values were the means of three consecutive samples (differing from each other by ≤15%) taken immediately before the first injection of test compound or vehicle. Microdialysis and behavioral data were analyzed using oneway or twoway repeated measures analysis of variance (ANOVA) and Tukey paired comparisons. To compare the effects of treatments in dialysis experiments, area under the curve (AUC) was calculated and expressed for each condition as a percentage of the AUC for the group receiving THC alone or WIN alone; simultaneous confidence intervals were used to determine whether the condition differed from 0% (thereby indicating a significant change from baseline) or 100% (thereby indicating a significant change versus the THCalone or WINalone group). Response rates in selfadministration experiments did not include responses or time elapsed during timeout. Selfadministration after Ro 618048 treatment was compared to that during the previous one to three consecutive sessions of vehicle treatment; for doseeffect curves, the last three sessions under each condition were averaged. Reinstatement data (extinction baseline and reinstatement test) represent the mean of one to three sessions under each condition. Working memory data (arcsinetransformed percentage of trials with a correct response) were analyzed with delay, THC dose and Ro 618048 dose as factors.
